Companies: 10,795·Total market cap: $144.5T
Standard BioTools Inc.

Standard BioTools Inc.

LABNASDAQHealthcare● Active
$0.80
$-0.35(-30.16%)
Market Cap$313543667
P/E Ratio—
52W High$1.72
52W Low$0.7953
Overview

Standard BioTools Inc.（LAB）股价预测与分析师目标价

华尔街共识、12 个月目标价、模型推演与 EPS/营收预期 — 来自分析师数据与历史行情。

lab · 股价预测 · 10 位分析师（近3月）· FMP · 更新于 2026年6月8日

分析师评级与共识

基于过去 3 个月内 10 位华尔街分析师

SellBuy

Buy

10 位分析师

共识

评级分布

Strong Buy
0
Buy
6
Hold
4
Sell
0
Strong Sell
0
合计: 10 · 买入占比: 60.0%

12 个月目标价

High

$3.25

Consensus

$3.25

+304.6% upside

Low

$3.25

Median: $3.25 · Last Close: $0.80

Standard BioTools Inc.（LAB）的分析师共识为 Buy，基于过去 3 个月内 10 位华尔街分析师的评级。LAB 的 12 个月平均目标价为 $3.25，相对当前价 $0.80 代表 +304.6% 的潜在上行空间。

12 个月目标价预测

历史收盘价 + 分析师 12 个月目标价预测区间

分析师目标价覆盖不足，无法为该股票生成预测图表。

短期股价预测

📅
财报窗口期

在 ±3 天财报窗口期内暂停短期预测，以避免不可靠信号。

长期股价预测

年度股价预测 · 2027 / 2028 / 2029 / 2030 / 2031

YearAvg PriceChange
2027$0-39.1%
2028$0-52.2%
2029$0-57.9%
2030$0-60.6%
2031—-62.0%
Confidence:Medium

基于技术分析的股价预测

14 项技术面信号（SMA×6 + EMA×6 + RSI + MACD）· EEAT 方法论透明

Elevated Volatility — Earnings Window Active (±3 days)· Technical signals still shown. M3 predictions paused.

Market Sentiment

BEARISH

Based on 14 technical indicators

7%7%86%
1Buy
1Neutral
12Sell
RSI (14)39.8Neutral
MACDBULLISH

Refreshes daily from EOD close

Moving Averages · LAB · Jun 8, 2026

Simple Moving Average (SMA)
MA 5$1.10SELL
MA 10$1.11SELL
MA 20$1.06SELL
MA 50$0.98SELL
MA 100$1.09SELL
MA 200$1.21SELL
Current $LAB · Price above MA = BUY signal
Exponential Moving Average (EMA)
EMA 5$1.05SELL
EMA 10$1.08SELL
EMA 20$1.06SELL
EMA 50$1.04SELL
EMA 100$1.08SELL
EMA 200$1.17SELL
Current $LAB · Price above MA = BUY signal
How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

最新分析师评级与调整

Filter:
TD Cowen2025-11-05
Maintains
Hold→Hold
Keybanc2025-02-27
Downgrade ↓
Overweight→Sector Weight
TD Cowen2024-10-31
Maintains
Buy→Buy
TD Cowen2024-08-01
Maintains
Buy→Buy
UBS2020-08-26
Maintains
Buy→Buy
UBS2020-08-09
Maintains
Buy→Buy
Janney Montgomery Scott2019-11-05
Downgrade ↓
Buy→Neutral
UBS2019-10-17
Upgrade ↑
Neutral→Buy
Janney Montgomery Scott2019-01-02
Upgrade ↑
Neutral→Buy
Piper Sandler2018-11-01
Upgrade ↑
Neutral→Overweight

Wall Street analysts have recently issued updated ratings on Standard BioTools Inc. (LAB) stock. Of the recent 26 rating actions, 8 were upgrades and 8 were downgrades. 10 analysts currently cover LAB.

分析师推荐趋势

Buy ratings0 → 0
Hold ratings1 → 1
Sell ratings0 → 0

LAB analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 0 to 0 per month.

财务预测：EPS 与营收一致预期

Revenue This Year

$80M

↓ 4.6% YoY

Revenue Next Year

$83M

↑ 2.8% YoY

EPS This Year

$-0.21

EPS Next Year

$-0.10

↓ 51.7% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast LAB EPS of $-0.21 for the current fiscal year, based on estimates from 1 analysts. The LAB revenue forecast is $80M for the current year. These are analyst consensus estimates via FMP / S&P Global.

关于预测与目标价

LAB 股价预测由两类独立数据源支撑：来自 10 位华尔街分析师（S&P Global / FMP）的共识评级，以及基于历史日终价计算的技术分析。LAB 的共识目标价为 $3.25（+304.6% 上行空间），分析师共识为 Buy。

LAB 对 2027 年的股价预测均值为 $0。 LAB 对 2030 年的预测区间为 $0–$0。

Standard BioTools Inc. 在 NASDAQ 上市，代码 LAB。LAB 在 2027 年的整体展望偏积极，在覆盖分析师中约 60% 对应 Buy 共识。

常见问题答案综合分析师目标价、一致预期及页面展示的模型结果。

相关页面

盈利营收市盈率财务报表市值内幕交易股息价格历史

常见问题

LAB 预测 · 8 个问题

根据 10 位华尔街分析师，LAB 的 12 个月平均目标价为 $3.25，最高 $3.25、最低 $3.25。若有图表，中位目标价可在上方查看。相对当前价 $0.80，隐含约 +304.6% 的上行空间。

LAB 目标价LAB 分析师目标价LAB 12个月目标价目标价 LAB

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.